COVANCE

Patrick McLaughlin, Executive Director
Anaheim Clinical Trials
1085 North Harbor Blvd
Anaheim, CA 92801

I have had the privilege of working with Mashgan Farand at Anaheim Clinical Trials in 2013. Mashgan was the Lead Study Coordinator assigned to an open-label, multi center, and single intravenous administration of an investigation drug to evaluate the pharmacokinetics (PK) and safety of an investigational drug in subjects with moderate and severe chronic hepatic impairment and matching healthy normal subjects.

This trial was exceedingly challenging in the fact that an Anesthesiologistt was working directly with the Principal Investigator (PI) during the dose administration process for continual subject monitoring and placing an arterial line for blood collection; PK analysis.

The Inclusion and Exclusion Criteria for the diseased population was very stringent in the area of recruitment for this clinical trial. Mashgan took on the task and worked to not only meet her required contractual number of subjects but to exceed her contractual number of subjects per sponsor approval.

Mashgan was amazing to work with, she made herself available to the site monitor and project management team seven days per week, as there were many times that dosing occurred over the weekend.

Mashgan was proactive in her communication techniques, not only did she utilize e-mail, phone contacts when necessary, she responded in virtually live time to text messaging allowing instantaneous communication to take place when required.

Mashgan is very intelligent, straightforward, and was willing to identify areas that required her additional attention.

Mashgan was focused on the safety of the subject first and foremost, Mashgan applied good clinical practice to all trial related activities. Meshgan shared her enthusiasm and energy with other team members. She was always prepared for a monitoring visit, queries were always resolved prior to the next monitoring visit, and data was entered within 24 hours of the subject visit.

Meshgan is not afraid to tackle difficult protocols as she welcomes a challenge. Mashgan has a great understanding of ICH-GCP guidelines and CFR Regulation. Mashgan is committed to furthering her knowledge in the area of clinical research. I have enjoyed the past year in working with Meshgan and wish her the best of luck in her future trials.

Mary Teague
Sr. CRA